@entity16332 and @entity28959 combination therapy with or without addition of @entity4020 for XXXX : a pilot study.

@entity1 @entity97 @entity16332 @entity1956 @entity6194 @entity4020 @entity28959 @entity13211
@entity16332 and @entity28959 combination therapy has been used in @entity1 with chronic @entity1956 to enhance the antiviral effect and reduce the risk of development of resistance. Interferon-alpha ( @entity4020 ) can theoretically be added to the regimen to further improve the antiviral effect. Twenty @entity1 with @entity6194 were given @entity16332 and @entity28959 combination therapy for 24 weeks. After 12 weeks of treatment, @entity1 were randomized on a 1:1 basis to either the addition of @entity4020 b or no addition for the last 3 months of therapy. The decline in @entity97 DNA levels, the loss of HBeAg and the HBeAg seroconversion rate were assessed. @entity1 with loss of HBeAg and/or development of anti-HBe were followed up for at least 1 y after stopping treatment. Four of 19 @entity1 (21%) had lost HBeAg and/or developed anti-HBe 24 weeks after stopping treatment, 1 of whom had received additional @entity4020 . During long-term follow-up post-treatment, 2/19 @entity1 (10.5%) had a durable HBeAg seroconversion. The mean @entity97 DNA level declined by 5 logs during the first 12 weeks of treatment. Addition of @entity4020 during the last 3 months of treatment did not result in any further decline in @entity97 DNA levels compared with the non- @entity4020 -treated group, nor in any increase in the @entity13211 seroconversion rate. In conclusion, @entity16332 and @entity28959 combination treatment induced seroconversion from HBeAg to anti-HBe in 4/19 @entity1 , 2 of whom became long-term responders. Addition of @entity4020 did not improve the seroconversion rate.
